<DOC>
	<DOC>NCT00252746</DOC>
	<brief_summary>To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively</brief_summary>
	<brief_title>ZD6474 Phase IIa Dose Finding Multicentre Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Provision of written informed consent. Life expectancy of 12 weeks or longer. Pregnancy, breast feeding or female patients wishing to become pregnant. Treatment with a nonapproved or investigational drug within 30 days before enrolment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Non Small Cell Lung Cancer</keyword>
</DOC>